HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARγ/RXR heterodimer

Journal of Endocrinology

Volumn 164, Issue 2, 2000, Pages

  Wentworth, J M ^a   Burris, T P ^b   Chatterjee, V K K ^a  

^a Department of Medicine ^*  (United Kingdom)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; ANTIRETROVIRUS AGENT; DEXAMETHASONE; INDINAVIR; INSULIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RETINOID X RECEPTOR; ROSIGLITAZONE; SAQUINAVIR;

ADIPOCYTE; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID METABOLISM; LIPODYSTROPHY; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTION;

EID: 0034007726     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.164r007     Document Type: Article

References (15)

1. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, Digby JE, Sewter CP, Lazar MA, Chatterjee VK & O'Rahilly S 1997a Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. Journal of Clinical Investigation 100 3149-3153.
2. Adams M, Reginato MJ, Shao D, Lazar MA & Chatterjee VK 1997b Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. Journal of Biological Chemistry 272 5128-5132.
3. Burris TP, Pelton PD, Zhou L, Osborne MC, Cryan E & Demarest KT 1999 A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation. Molecular Endocrinology 13 410-417.
4. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ & Cooper DA 1998a A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. Aids 12 F51-F58.
5. Carr A, Samaras K, Chisholm DJ & Cooper DA 1998b Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351 1881-1883.
6. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ & Cooper DA 1999 Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353 2093-2099.
7. Collingwood TN, Adams M, Tone Y & Chatterjee VK 1994 Spectrum of transcriptional, dimerization, and dominant negative properties of twenty different mutant thyroid hormone beta-receptors in thyroid hormone resistance syndrome. Molecular Endocrinology 8 1262-1277.
8. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, Raventos A, Rubio R, Bouza E, Pintado V et al. 1995 A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. New England Journal of Medicine 333 1528-1533.
9. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, Chodakewitz JA & Fischl MA 1997 A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team [see comments]. New England Journal of Medicine 337 725-733.
10. Jackson SN, Howlett TA, McNally PG, O'Rahilly S & Trembath RC 1997 Dunnigan-Kobberling syndrome: an autosomal dominant form of partial lipodystrophy. Qjm 90 27-36.
11. Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B, Feigenbaum L, Lee E, Aoyama T, Eckhaus M, Reitman ML & Vinson C 1998 Life without white fat: a transgenic mouse. Genes and Development 12 3168-3181.
12. Tontonoz P, Hu E & Spiegelman BM 1994a Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79 1147-1156.
13. Tontonoz P, Graves RA, Budavari AI, Erdjument-Bromage H, Lui M, Hu E, Tempst P & Spiegelman BM 1994b Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR gamma and RXR alpha. Nucleic Acids Research 22 5628-5634.
14. Tontonoz P, Hu E, Graves RA, Budavari AI & Spiegelman BM 1994c mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes and Development 8 1224-1234.
15. Tontonoz P, Hu E & Spiegelman BM 1995 Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Current Opinion in Genetics and Development 5 571-576.